

Julie Bertrand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5538852/publications.pdf>

Version: 2024-02-01

27
papers

647
citations

686830

13
h-index

610482

24
g-index

29
all docs

29
docs citations

29
times ranked

1018
citing authors

#	ARTICLE	IF	CITATIONS
1	Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1452-1463.	1.1	6
2	Towards safer risperidone prescribing in Alzheimer's disease. <i>British Journal of Psychiatry</i> , 2021, 218, 268-275.	1.7	9
3	Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 340-349.	1.3	1
4	Bayesian inference using Hamiltonian Monte Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. <i>Statistics in Medicine</i> , 2020, 39, 4853-4868.	0.8	11
5	New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling. <i>AAPS Journal</i> , 2020, 22, 141.	2.2	3
6	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 509-514.	1.3	170
7	Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM. <i>AAPS Journal</i> , 2020, 22, 50.	2.2	5
8	Bioequivalence and Statistics in Clinical Pharmacology. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 728-729.	0.4	3
9	Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 396-404.	1.3	18
10	Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2120-2128.	1.3	7
11	Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. <i>Brain</i> , 2017, 140, 1117-1127.	3.7	40
12	Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	3
13	A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e844-e851.	1.1	13
14	Can a Flavored Spray (Pill Glide) Help Children Swallow Their Medicines? A Pilot Study. <i>Pediatrics</i> , 2016, 138, e20160680-e20160680.	1.0	18
15	A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease. <i>Psychopharmacology</i> , 2016, 233, 3371-3381.	1.5	18
16	Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 231-238.	0.7	3
17	Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates. <i>AAPS Journal</i> , 2015, 17, 597-608.	2.2	5
18	Dependence of Efavirenz- and Rifampicin-Isoniazid-Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia. <i>Journal of Infectious Diseases</i> , 2014, 209, 399-408.	1.9	45

#	ARTICLE	IF	CITATIONS
19	Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 167-174.	0.7	13
20	Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 868-876.	0.7	31
21	Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose-Response Models. <i>AAPS Journal</i> , 2012, 14, 420-432.	2.2	42
22	Some Alternatives to Asymptotic Tests for the Analysis of Pharmacogenetic Data Using Nonlinear Mixed Effects Models. <i>Biometrics</i> , 2012, 68, 146-155.	0.8	13
23	Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model. <i>AAPS Journal</i> , 2011, 13, 390-404.	2.2	22
24	Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4432-4439.	1.4	38
25	Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 317-339.	0.8	33
26	Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 667-678.	0.8	35
27	Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters. <i>Journal of Biopharmaceutical Statistics</i> , 2008, 18, 1084-1102.	0.4	35